HUNTERSVILLE, N.C., June 2, 2008 – Orthofix International N.V. (NASDAQ:OFIX) (the Company) announced today that through its subsidiary, Orthofix, Inc., it has entered into a 10-year exclusive license agreement with Texas Scottish Rite Hospital for Children (TSRHC) extending their current collaboration which provides the TRUE/LOK™ External Fixation System to the global orthopedic market. 

Through Orthofix, Inc., the Company develops, manufactures and distributes fixation devices for the $350 million global external fixation market. TRUE/LOK™ is a versatile, lightweight system designed to correct limb deformities, treat bone fractures and lengthen limbs using a simpler frame. In addition to marketing the current TRUE/LOK™ system, the arrangement provides for TSRHC and Orthofix to collaborate in the development and marketing of future versions of the TRUE/LOK™ system introduced to the medical community during the term of the agreement.

Researchers at TSRHC first developed the TRUE/LOK™ External Fixation System in 1993, which is a modified design of the device created by Dr. Gavriil Ilizarov of Russia. Having studied under Dr. Ilizarov, researchers at TSRHC were able to create TRUE/LOK™, which is considered one of the most advanced circular fixators. Orthofix first obtained the rights to market TRUE/LOK™ in 2006. Since that time, the Company and TSRHC have trained an extensive number of surgeons in the U.S. and around the world in the use of the device through both the hospital’s training programs and the Orthofix Training Academy.

“Texas Scottish Rite Hospital for Children is pleased to continue working with Orthofix to help thousands of children treated at TSRHC and worldwide with bone injuries and limb-length differences,” said J. C. Montgomery, Jr., president of Texas Scottish Rite Hospital for Children. “Patient care, research and education are the pillars of TSRHC’s orthopedic work, and this collaboration represents an important opportunity to provide better treatments for our patients, to further research and continue to advance professional medical education.”

Michael Simpson, President of Orthofix Inc, said “For over thirty years Orthofix has been dedicated to the advancement of external fixation treatments for patients. We look forward to our continued collaboration with Texas Scottish Rite Hospital for Children, which is renowned globally as a world-class healthcare provider. We are excited to have the opportunity to work with TSRHC to continue bringing these important advances in treatment to patients around the world.”

Orthofix International’s CEO, Alan Milinazzo, added, “this agreement demonstrates the Company’s commitment to maintain its role as a significant participant in the global orthopedic fixation market. This collaboration partnership is an important example of our ongoing focus on the development of innovative, minimally invasive treatments around the world.”

About Orthofix:
Orthofix International, N.V., a global diversified orthopedic products company, offers a broad line of minimally invasive surgical, and non-surgical, products for the spine, orthopedic, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages–helping them achieve a more active and mobile lifestyle. Orthofix’s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix’s sales representatives and its subsidiaries, including BREG, Inc. and Blackstone Medical, Inc., and via partnerships with other leading orthopedic product companies. In addition, Orthofix is collaborating in R&D partnerships with leading medical institutions such as the Orthopedic Research and Education Foundation, Rutgers University, the Cleveland Clinic Foundation, Texas Scottish Rite Hospital for Children and National Osteoporosis Institute. For more information about Orthofix, please visit www.orthofix.com.

About TSRHC:
Texas Scottish Rite Hospital for Children is one of the nation's leading pediatric centers for the treatment of orthopedic conditions, certain related neurological disorders and learning disorders, such as dyslexia. There is no charge to patient families for treatment at the hospital, and admission is open to Texas children from birth to 18 years of age. For more information, to volunteer or to make a donation, please call (214) 559-5000 or (800) 421-1121 or visit www.tsrhc.org.

FORWARD-LOOKING STATEMENTS
This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.

Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the expected sales of its products, including recently launched products, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, changes to and interpretation of governmental regulation of medical devices, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry and the economy, corporate development and market development activities, including acquisitions or divestitures, unexpected costs or operating unit performance related to recent acquisitions and other factors described in our annual report on Form 10-K and other periodic reports filed by the Company with the Securities and Exchange Commission.

# # #